JPH0765879B2 - Infrared flare - Google Patents

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a flare generating infrared rays, and more particularly to a decoy flare for an infrared homing vehicle.

[0002]

2. Description of the Related Art Conventionally, infrared flare has been used for various purposes. For example, U.S. Pat. No. 3,733,223 is disclosed as an illumination that emits infrared rays in order to effectively utilize a night-vision device. It is also used for decoy flare because the aircraft escapes from infrared-tracking vehicles. This decoy flare is mainly composed of hydrocarbons such as gasoline,
U.S. Pat. No. 4,171,669, which is mainly composed of red phosphorus, is disclosed in U.S. Pat.
4,186. The decoy flare, which is a conventional anti-aircraft aircraft, is mainly composed of magnesium and Teflon (registered trademark).
positives, Propellents and
Pyrotechnics, BRASSEY'S (U
K) (1989, P135). Decoy flare is ineffective unless the infrared radiation is increased to the maximum radiation intensity within a short time after ignition. Therefore, a method of opening 12 pores on the circumference of the decoy flare and passing the same composition as a string-shaped flare called "spaghetti" through these pores is AD-D000561, published by NTIS.
"Flare", Kenneth K. Foote, 4
Nov. In 1974, U.S. Patent Application 1974-S
ERIAL No. No. 520,381. In general, since the ignition source for igniting the infrared flare has a small amount of energy, a chemical that ignites with low energy is applied, and the infrared flare body is ignited by the combustion heat of the chemical.

[0003]

However, the conventional method of igniting infrared flare has a drawback that a pit A in which the infrared radiation intensity sharply decreases at the initial stage of combustion is generated as shown in FIG. Such a depression A is generated because the combustion speed of the medicine that is ignited with low energy from the ignition source is high, and thus the combustion of the medicine is completed before the infrared flare body reaches steady combustion. The present invention has been made to solve the above-mentioned conventional problems, and an object thereof is to make it possible to suppress an abrupt decrease in luminous intensity that occurs while combustion of the infrared flare body reaches a steady state from ignition. To provide flare.

[0004]

According to a first aspect of the present invention, there is provided an infrared flare body having a groove on its surface, a second drug layer formed by applying a second drug to the groove of the infrared flare body, and the second drug. A first drug layer formed by applying a first drug having a burning rate faster than that of the second drug on the entire surface of the infrared flare body having a layer formed thereon, and a laminated film covering the first drug layer. The present invention provides an infrared flare having a high initial burning rate without the above-mentioned depression. Further, the second aspect of the present invention provides an infrared flare in which the laminated film is composed of a laminate of aluminum foil and polytetrafluoroethylene reinforced with glass fiber and exhibits the same or higher effect.

The infrared flare body according to the present invention is made of, for example, magnesium 60 to 60, like the conventional infrared flare.
It is composed of 65%, polytetrafluoroethylene 15 to 25%, and fluororubber 10 to 20%. The burning rate of this composition is about 1.8 mm / sec. The shape of the infrared flare body is arbitrary and is, for example, a rectangular parallelepiped, a cube, a cylinder, or a polygonal prism. The groove formed on the surface of the infrared flare body is arbitrary as long as it has a shape capable of applying the viscous second drug, and the number thereof can be appropriately selected according to the application and purpose. it can. The second agent receives energy from the first agent and burns, and the combustion heat ignites the infrared flare body. The second agent is a viscous agent applied to the infrared flare body, and is composed of, for example, 50 to 60% magnesium, 30 to 40% polytetrafluoroethylene, and 5 to 15% fluororubber, and its burning rate. Is higher than the burning rate of the infrared flare body, for example, magnesium 55%, polytetrafluoroethylene 35%, and fluororubber 10%.
When it is composed of and, it is about 15 mm / sec.
The second drug layer is formed by applying the second drug over the entire length of the groove of the infrared flare body.

The first agent is a viscous agent applied to the entire surface of the infrared flare body having the second agent layer formed thereon. For example, magnesium 65-75%, polytetrafluoroethylene 15-25% and fluorine. It is composed of rubber 5 to 15%. The first drug layer is formed by applying the first drug on the entire surface of the infrared flare body on which the second drug layer is formed. When the first drug is applied thickly, the corrugations of the infrared radiation are alleviated. However, increasing the coating amount of the first drug to thicken the first drug layer reduces the size of the infrared flare body, which is not preferable. An object of the present invention is to obtain an infrared flare satisfying a predetermined target by increasing the size of the infrared flare body as much as possible, that is, reducing the amounts of the first drug and the second drug.
Therefore, the thinner the first medicine, the better, if the target performance is satisfied. Further, the burning rate of the first chemical is set to be faster than the burning rates of the infrared flare body and the second chemical. For example, when the composition is composed of 70% magnesium, 20% polytetrafluoroethylene and 10% fluororubber, the burning rate of the first chemical is about 22 mm / sec.
Then, the burning speed of the above infrared flare body is about 1.8 mm
/ Sec and the burning rate of the second drug are higher than about 15 mm / sec.

The laminated film is formed on the first drug layer in order to quickly transfer the combustion to the entire surface of the first drug. As the laminated film, for example, an aluminum foil having a thickness of about 0.1 mm and a reinforced glass fiber woven fabric having a thickness of about 0.
It is composed of a laminate with 2 mm of polytetrafluoroethylene. Here, as a method of reinforcing the polytetrafluoroethylene with the glass fiber woven cloth, for example, the glass fiber woven cloth is stuck to the polytetrafluoroethylene, or the glass fiber woven cloth is impregnated with the polytetrafluoroethylene.

[0008]

In the present invention, for example, as shown in FIG. 1, ten grooves 2 having a width of 3 mm and a depth of 2.5 mm are provided on the surface in the longitudinal direction, width 48 mm, height 22 mm, length 1
A 60 mm rectangular parallelepiped infrared flare main body 1 is molded, and then each groove 2 is coated with a viscous second drug to form a second drug layer 3. Next, the first drug layer 4 is formed by applying a viscous first drug having a faster burning rate than the second drug to the entire surface of the infrared flare body 1 on which the second drug layer 3 is formed. Finally, the laminated film 5 is attached onto the first drug layer 4 with an adhesive. By the above, an infrared flare can be formed.

When the infrared flare thus formed receives energy from an ignition source having a small amount of energy, the first chemical agent in the first chemical agent layer 4 is easily ignited, and the laminated film 5 and the first chemical agent layer 4 are ignited.
The flame propagates through the gap between the medicine layer 4 and the entire surface of the first medicine layer 4 burns quickly. Due to this combustion, the intensity of infrared rays sharply increases as shown in FIG. Since the amount of the first first drug applied to the surface is small, the combustion ends quickly, but when the combustion reaches the maximum, the second drug applied to the groove 2 of the infrared flare body 1 is removed. The first drug is burned and the second drug layer 3 starts to burn. As a result, as shown in FIG. 2B, the decrease in the infrared intensity of the first drug is supplemented by the combustion by the second drug before the end of the combustion of the first drug, and the decrease in the infrared intensity is prevented. at the same time,
The burning of the infrared flare body 1 also partially starts. At the time when the first combustion of the first chemical is completed, the combustion of the second chemical reaches the maximum, and the combustion of the infrared flare body 1 is also shifting to steady combustion. At the time when the combustion of the second chemical is completed, the combustion of the infrared flare main body 1 reaches steady combustion as shown in FIG. Therefore, the infrared intensity can be maintained from the start of combustion to the combustion of the infrared flare body 1 without a decrease in infrared intensity.

[0010]

FIG. 1 is a partially cutaway perspective view of an infrared flare according to the present invention, FIG. 2 is a graph showing the relationship between the intensity of infrared rays emitted from the infrared flare according to Example 1 and time, and FIG. FIG. 4 is a graph showing the relationship between the intensity of infrared rays emitted from the infrared flare according to Comparative Example 1 and time, and FIG. 4 is a graph showing the relationship between the intensity of infrared rays emitted from the infrared flare according to Comparative Example 2 and time. .

Embodiment 1. Magnesium (200-325
(Particles of mesh) 65%, polytetrafluoroethylene 20%, and fluororubber 15%. As shown in FIG. 1, the longitudinal surface has a width of 3 mm and a depth of 2.5 m.
having 10 grooves 2 of m, width 48 mm, height 22 mm,
A rectangular parallelepiped infrared flare body 1 having a length of 160 mm is molded. Next, in each groove 2, magnesium (200 to 325)
55% of mesh particles), 35% of polytetrafluoroethylene and 10% of fluororubber are applied to apply a viscous second chemical agent to form a second chemical agent layer 3. In addition, this second
70% magnesium (particles smaller than 325 mesh), 20% polytetrafluoroethylene, and 10% fluororubber on the entire surface of the infrared flare body 1 on which the drug layer 3 is formed.
The first drug layer 4 is formed by applying a viscous first drug consisting of. The burning rate of this first drug is about 22 mm / se.
In c, the burning speed of the second chemical is higher than about 15 mm / sec. The burning rate of the infrared flare body is
It is about 1.8 mm / sec. Finally, a laminated film 5 made of a laminate of an aluminum foil having a thickness of about 0.1 mm and a polytetrafluoroethylene having a thickness of about 0.2 mm reinforced with a glass fiber woven cloth is adhered onto the first chemical layer 4 as an adhesive. Pasted through. The infrared flare thus formed is burned, and the infrared intensity at that time is measured with a radiometer Model.
SA-10 (Minarad Systems of the United States
INC. Manufactured), as shown in FIG.
No dent was generated in the infrared intensity waveform.

Comparative Example 1. An infrared flare having no laminated film 5 in Example 1 was prepared. When this infrared flare was burned in the same manner, as shown in FIG. 3, no pit was formed in the infrared intensity waveform, but the time required for the infrared radiation to reach its maximum was longer than in Example 1. This means that it is not suitable as a decoy flare that requires a short time from ignition to maximum infrared radiation intensity.

Comparative Example 2. The same infrared flare main body 1 as in Example 1 was prepared, and the viscous first agent having the same composition as in Example 1 was applied to the entire surface including the groove 2 of the infrared flare main body 1. Further, as in Example 1, On this first drug layer 4, a thickness of about 0.1 m
m of aluminum foil and about 0.2 mm of polytetrafluoroethylene reinforced with glass fiber woven cloth and a laminated film 5 made of a laminate were attached via an adhesive. The infrared flare thus obtained was burned, and the infrared intensity at that time was measured with a radiometer Model SA-10. As a result, as shown in FIG. 4, a depression A was generated in the infrared intensity waveform.

Comparative Example 3. The same infrared flare main body as in Example 1 was prepared, and 55% of magnesium (100-200 mesh particles) having a slower burning rate than the second chemical used in Example 1 and 35% of polytetrafluoroethylene were prepared in the groove 2 thereof.
A viscous chemical consisting of 10% of fluororubber and fluororubber is applied, and 70% of magnesium (particles smaller than 325 mesh), 20% of polytetrafluoroethylene and 20% fluororubber are coated on the entire surface of the infrared flare body on which the chemical layer is formed. A viscous first drug consisting of 10% was applied to form a first drug layer. Further, a laminated film 5 made of a laminate of an aluminum foil having a thickness of about 0.1 mm and a polytetrafluoroethylene having a thickness of about 0.2 mm reinforced with a glass fiber woven fabric is formed on the first drug layer as in Example 1. It was attached via an adhesive. When the infrared flare thus obtained was burned and the infrared intensity at that time was measured with a radiometer Model SA-10, a dent was generated in the waveform of the infrared intensity as in Comparative Example 2.

Example 2. Magnesium (200-325
60% of mesh particles), 25% of polytetrafluoroethylene and 15% of fluororubber. As shown in FIG. 1, the longitudinal surface has a width of 3 mm and a depth of 2.5 m.
having 10 grooves 2 of m, width 48 mm, height 22 mm,
A rectangular parallelepiped infrared flare body 1 having a length of 160 mm is molded. Next, in each groove 2, magnesium (200 to 325)
55% of mesh particles), 35% of polytetrafluoroethylene and 10% of fluororubber are applied to apply a viscous second chemical agent to form a second chemical agent layer 3. In addition, this second
70% magnesium (particles smaller than 325 mesh), 20% polytetrafluoroethylene, and 10% fluororubber on the entire surface of the infrared flare body 1 on which the drug layer 3 is formed.
The first drug layer 4 is formed by applying a viscous first drug consisting of. Finally, a laminated film 5 made of a laminate of aluminum foil having a thickness of about 0.1 mm and polytetrafluoroethylene having a thickness of about 0.2 mm reinforced with a glass fiber woven cloth is adhered onto the first chemical layer 4 as an adhesive. Pasted through. The infrared flare thus formed is burned, and the infrared intensity at that time is measured with a radiometer Moldel SA-10.
As a result of the measurement, the pits did not occur in the infrared intensity waveform as in Example 1.

[0016]

As described above, according to the present invention, when the energy is received from the ignition source having a small amount of energy, the first drug of the first drug layer is easily ignited, and the gap between the laminated film and the first drug layer is generated. The flame propagates and promptly burns the entire surface of the first drug layer. Due to this combustion, the infrared intensity reaches the maximum in a short time. At the same time, when the combustion of the first agent reaches the maximum, the second agent applied to the groove of the infrared flare body becomes the first agent.
The second drug layer starts to burn due to the burning of the drug. As a result, the decrease in the infrared intensity of the first chemical is supplemented by the combustion by the second chemical before the end of the combustion of the first chemical, and the decrease in the infrared intensity is prevented. That is, it is possible to prevent the occurrence of depressions in which the infrared radiation intensity sharply decreases in the conventional infrared flare. Further, when the first combustion of the first chemical is completed, the combustion of the second chemical reaches the maximum, and the combustion of the infrared flare body is also shifting to steady combustion. Then, when the combustion of the second chemical is completed, the combustion of the infrared flare body reaches the steady combustion. Therefore,
According to the present invention, the infrared intensity has the advantage that it can be maintained without decreasing from the start of combustion to the combustion of the infrared flare body, which is a very useful invention.

[Brief description of drawings]

FIG. 1 is a partially cutaway perspective view of an infrared flare according to an embodiment of the present invention.

FIG. 2 is a graph showing the relationship between the intensity of infrared rays emitted from an infrared flare and time according to an example of the present invention.

FIG. 3 is a graph showing the relationship between the intensity of infrared rays emitted from the infrared flare and time according to Comparative Example 1.

FIG. 4 is a graph showing the relationship between the intensity of infrared rays emitted from an infrared flare according to Comparative Example 2 and time.

[Explanation of symbols]

 1 Infrared flare body 2 Groove 3 Second drug layer 4 First drug layer 5 Laminated film

 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Keimasa Suzuki Keigo, Nishigokawa, Nishishirakawa-gun, Fukushima Daiichi Nagasaka, Dou No. 1 1 Shirakawa Laboratory, Nippon Koki Co., Ltd. (72) Koharu Sato, Saigomura, Nishishirakawa-gun, Fukushima Prefecture 1 in Shirakawa Laboratory, Nippon Kouki Co., Ltd. (72) Inventor Yoshikazu Sugi, Saigo Village, Nishishirakawa-gun, Fukushima Prefecture 2 in 1 Shirakawa Laboratory, Nippon Koki Co., Ltd.

Claims (2)

[Claims] 1. An infrared flare body having a groove on its surface,
A second drug layer formed by applying a second drug to the groove of the infrared flare body, and a second drug layer having a higher burning rate than the second drug on the entire surface of the infrared flare body having the second drug layer formed thereon. An infrared flare comprising a first drug layer formed by applying one drug, and a laminated film covering the first drug layer. 2. The infrared flare according to claim 1, wherein the laminated film is composed of a laminate of aluminum foil and polytetrafluoroethylene reinforced with glass fiber.